Register for January 24, 2018 Webinar


Wednesday, January 24, 2018, 2:00 PM - 3:00 PM EST 

Program Description 

Spinal Muscular Atrophy: Patient Outcomes and Cost Considerations 

Spinal muscular atrophy (SMA) is a rare, genetic, neuromuscular disease that causes progressive muscle weakness and deterioration. SMA is categorized into four types, depending on the severity of the disease, and each type presents its own unique clinical management challenges. Due to this heterogeneity, the impact of SMA on mortality and quality of life varies among patients.

In this webinar, experts will explore the clinical aspects of SMA—including symptoms, diagnosis and treatment options— and address cost containment strategies.

Learning Objectives 

At the completion of this activity, participants should be able to:

  1. Explain the classification, signs and symptoms, and potential comorbidities of spinal muscular atrophy (SMA).
  2. Using SMA classification categories as a guide, identify non-pharmacologic and pharmacologic approaches to managing patients with SMA.
  3. Discuss cost containment strategies for the management of SMA.

Target Audience 

This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.

Faculty Presenters  

Stephen J. Ryan, MD, MA
University of Kentucky Medical Center
Lexington, Kentucky


Jack Hoadley, PhD
Research Professor Emeritus
Georgetown University
Washington, DC



Brittany N. Vogel, PharmD, MBA
Education Program Manager
Academy of Managed Care Pharmacy
Alexandria, Virginia

2:00 pm to 2:05 pm        Welcome and Introductions
Brittany N. Vogel, PharmD, MBA 
2:05 pm to 2:30 pm   Spinal Muscular Atrophy – A Review of Clinical Presentations and Treatment Options
Stephen J. Ryan, MD, MA 
2:30 pm to 2:50 pm   Managed Care Considerations for Spinal Muscular Atrophy
Jack Hoadley, PhD 
2:50 pm to 3:00 pm   Audience Q&A
Brittany N. Vogel, PharmD, MBA

ACPE UAN #: 0233-0000-18-001-L04-P

Credit: 1.0 contact hours (0.1 CEU)

Activity Type: Knowledge-based

Activity Fee: There is no fee to participate in this activity.

 ACPE LogoThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

 AMCP Logo 

Earning CPE Credit 

To earn CPE, you must attend the entire session and participation in the pre- and post-test questions is required. Once completed, go to to claim continuing pharmacy education (CPE) credit for this program. In the enrollment code redemption area, enter the enrollment code provided during the session. Complete the program evaluation and enter your NABP ID, birth month and birth day. All CPE credit for this webinar activity must be completed no later than 5:00 PM EST on February 26, 2018. No exceptions can be made after this date.

Statement of Commercial Support 

This educational activity is supported by an unrestricted educational grant from Biogen MA, Inc.


This continuing education activity is provided at no cost to participants, but space is limited to the first 500 participants that join the webinar.

System Technical Requirements/Viewing Requirements  

For all activities you should have a basic comfort level using a computer and navigating web sites.

The live webinar is delivered through GoToWebinar. To view minimum technical and system requirements for the webinar, please use your web browser to check your system requirements by clicking here. Space is limited to the first 500 participants that join the webinar.

The handout will be delivered via Acrobat PDF.

CPE credit will be claimed through AMCP Learn. View the minimum technical and system requirements for continuing education online learning activities by clicking here.